SCHEMBL23748593

SCHEMBL23748593

O=C(CCl)Nc1ccc(Oc2cccc(C(F)(F)F)c2)cc1

nearest known ligand 0.66

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
RNF4 P78317 1/20 0.66
TLR8 Q9NR97 3/20 0.61
TLR7 Q9NYK1 2/20 0.61
MITF O75030 1/20 0.61
ALDH1A1 P00352 1/20 0.61
POLB P06746 1/20 0.61
MAPK1 P28482 1/20 0.61
HTT P42858 1/20 0.61
BRAF P15056 1/20 0.55
KDR P35968 1/20 0.55
MAPK14 Q16539 1/20 0.55
TNNI3K Q59H18 1/20 0.55
KMT2A Q03164 2/20 0.52
GAA P10253 2/20 0.51
MEN1 O00255 1/20 0.51
MAPT P10636 1/20 0.51
XBP1 P17861 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
MTNR1A P48039 2/20 0.51
MTNR1B P49286 2/20 0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL23748592 0.86 RNF4 (0.68) RNF4MITFALDH1A1POLBMAPK1
SCHEMBL11581513 0.83 KIF11 (0.64) TLR8TLR7HTTBRAFKDR
SCHEMBL14384680 0.83 MTNR1A (0.66) TLR8TLR7HTTBRAFKDR
SCHEMBL21392901 0.83 RNF4 (0.71) RNF4MITFALDH1A1POLBMAPK1
SCHEMBL31703396 0.81 RNF4 (0.73) RNF4MITFALDH1A1POLBMAPK1
SCHEMBL965028 0.81 MAPT (0.70) ALDH1A1HTTKMT2AGAAMEN1
SCHEMBL11276153 0.81 TP53 (0.68) TLR8TLR7BRAFKDRMAPK14
SCHEMBL11583889 0.81 KDR (0.63) TLR8TLR7HTTBRAFKDR
SCHEMBL3382618 0.80 RNF4 (1.00) RNF4MITFALDH1A1POLBMAPK1
SCHEMBL11806908 0.80 RNF4 (0.86) RNF4MITFALDH1A1POLBMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-113164495-B Covalent targeting of E3 ligases 加利福尼亚大学董事会 2025-04-22 CN disclosed
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2025-04-17 US disclosed
US-12161648-B2 Covalent targeting of E3 ligases THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) 2024-12-10 US disclosed
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF DANA-FARBER CANCER INSTITUTE, INC. (US) 2023-06-22 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES THE REGENTS OF THE UNIVERSITY OF CALIFORNIA 2021-12-02 US disclosed
EP-3863642-A1 COVALENT TARGETING OF E3 LIGASES The Regents of the University of California (US) 2021-08-18 EP disclosed
CN-113164495-A Covalent targeting of E3 ligase 加利福尼亚大学董事会 2021-07-23 CN disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12161648-B2 Covalent targeting of E3 ligases RNF114, RNF4, RNF168 RNF4 2/4885TLR8 4147/4885TLR7 4740/4885
US-20210369731-A1 COVALENT TARGETING OF E3 LIGASES RNF114, RNF4, RNF168 RNF4 2/4885TLR8 4147/4885TLR7 4740/4885
US-20230192607-A1 TRANSCRIPTIONAL ENHANCED ASSOCIATE DOMAIN (TEAD) TRANSCRIPTION FACTOR INHIBITORS AND USES THEREOF TEAD1, TEAD4, TEAD2 RNF4 2075/4885TLR8 2797/4885TLR7 2844/4885
US-20250120982-A1 COVALENT TARGETING OF E3 LIGASES STUB1, XIAP, RBX1 RNF4 13/4885TLR8 3453/4885TLR7 4291/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.